Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans

Chemical Research in Toxicology

Volumn 16, Issue 1, 2003, Pages 38-47

  Stiborová, Marie ^a   Stiborová Rupertová, Martina ^a   Bořek Dohalská, Lucie ^a   Wiessler, Manfred ^b   Frei, Eva ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; DEOXYGUANOSINE; DNA TOPOISOMERASE (ATP HYDROLYSING); ELLIPTICINE; POLYDEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASE PAIRING; CONTROLLED STUDY; COVALENT BOND; DNA ADDUCT; DNA BINDING; DRUG ACTIVATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERCALATION COMPLEX; LIVER MICROSOME; MOLECULAR MODEL; NONHUMAN; RABBIT; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEOXYGUANOSINE; DNA; DNA ADDUCTS; ELLIPTICINES; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MODELS, ANIMAL; PHOSPHORUS RADIOISOTOPES; RABBITS; RATS; SPECIES SPECIFICITY;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 12244292673     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0200818     Document Type: Article

References (40)

1. Stiborová, M., Bieler, C. A., Wiessler, M., and Frei, E. (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem. Pharmacol. 62, 1675-1684.
2. Auclair, C. (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch. Biochem. Biophys. 259, 1-14.
3. Singh, M. P., Hill, G. C., Peoch, D., Rayner, B., Inabach, J. L., and Lown, J. W. (1994) High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33, 10271-10285.
4. Chu, Y., and Hsu, M. T. (1992) Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. Nucleic Acids Res. 20, 4033-4038.
5. Monnot, M., Mauffret, O., Simon, V., Lescot, E., Psaume, B., Saucier, J. M., Charra, M., Belehradek, J., Jr., and Fermandjian, S. (1991) DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J. Biol. Chem. 25, 1820-1829.
6. Fossé, P., René, B., Charra, M., Paoletti, C., and Saucier, J. M. (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol. Pharmacol. 42, 590-595.
7. Froelich-Ammon, S. J., Patchan, M. W., Osheroff, N., and Thompson, R. B. (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J. Biol. Chem. 270, 14998-15004.
8. Ohashi, M., Sugikawa, E., and Nakanishi, N. (1995) Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn. J. Cancer Res. 86, 819-829.
9. Schwaller, M. A., Allard, B., Lescot, E., and Moreau. F. (1995) Protonophoric activity of ellipticine and isomers across the energytransducing membrane of mitochondria. J. Biol. Chem. 270, 22709-22713.
10. Murray, G. I., Weaver, R. J., Paterson, P. J., Ewen, S. W., Melvin, W. T., and Burke, M. D. (1993) Expression of xenobiotic metabolizing enzymes in breast cancer. J. Pathol. 169, 347-353.
11. Murray, G. I., Melvin, W. T., and Burke, M. (1995) Cytochrome P450 expression in tumors. J. Pathol. 3, 147-152.
12. Patterson, L. H., McKeown, S. R., Robson, T., Gallagher, R., Raleigh, S. M., and Orr, S. (1999) Antitumor prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Des. 14, 473-486.
13. Frei, E., Bieler, C. A., Arlt, V. M., Wiessler, M., and Stiborová, M.(2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem. Pharmacol. 64, 289-295.
14. 13C NMR spectroscopy. J. Org. Chem. 55, 1792-1796.
15. 32P-postlabelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18, 1063-1067.
16. 32P-post-labeling: evidence for reductive activation by peroxidases. Carcinogenesis 18, 1055-1062.
17. Evans, E. A. (1974) Tritium and its compounds, Butterworth & Co Ltd., London.
18. 32P-postlabeling of DNA adducts derived from peroxidative activation of carcinogenic non-aminoazo dye 1-phenylazo-2-hydroxynaphthalene (Sudan I). Carcinogenesis 11, 1843-1948.
19. Stiborová, M., Asfaw, B., Frei, E., Schmeiser, H. H., and Wiessler, M. (1995) Benzenediazonium ion derived from Sudan I forms an 8-(phenylazo)guanine adduct in DNA. Chem. Res. Toxicol. 8, 489-498.
20. Hodek, P., Janšcák, P., Anzenbacher, P., Burkhard, J., Janku, J., and Vodicka, L. (1988) Metabolism of diamantane by rat liver microsomal cytochrome P-450. Xenobiotica 18, 1109-1118.
21. Gut, I., Nedelcheva, V., Soucek, P., Stopka, P., Vodicka, P., Gelboin, H. V., and Ingelman-Sundberg, M. (1996) The role of CYP2E1 and 2B1 in metabolic activation of benzene derivatives. Arch. Toxicol. 71, 45-56.
22. Stiborová, M., Bořek-Dohalská, L., Hodek, P., Mráz, J., and Frei, E. (2002) New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch. Biochem. Biophys. 403, 41-49.
23. Bořek-Dohalská, L., Hodek, P., Šulc, M., and Stiborová, M. (2001) α-Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem.-Biol. Interact. 138, 85-106.
24. Anzenbacher, P., Souček, P., Anzenbacherová, E., Gut, I., Hrubý, K., Svoboda, Z., and Květina, J. (1998) Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. Drug Metab. Dispos. 26, 56-59.
25. Wiechelman, K. J., Braun, R. D., and Fitzpatrick, J. D. (1988) Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal. Biochem. 175, 231-237.
26. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378.
27. Guengerich, F. P., and Shimada, T. (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem. Res. Toxicol. 4, 391-407.
28. Stiborová, M., Martínek, Rydlová, H., Hodek, P., and Frei, E. (2002) Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 62, 5678-5684.
29. Haugen, D. A., and Coon, M. J. (1976) Properties of electrophoretically homogeneous phenobarbital-inducible and betanaphthoflavone-inducible forms of liver microsomal cytochrome P-450. J. Biol. Chem. 251, 7929-7939.
30. Yang, C. S., Tu, Y. Y., Koop, D. R., and Coon, M. J. (1985) Metabolism of nitrosamines by purified rabbit liver cytochrome P-450 isozymes. Cancer Res. 45, 1140-1145.
31. Saito, T., and Strobel, H. W. (1981) Purification to homogeneity and characterization of a form of cytochrome P-450 with high specificity for benzo[alpyrene from β-naphthoflavone-pretreated rat liver microsomes. J. Biol. Chem. 256, 984-988.
32. Yasukochi, Y., Peterson, J. A., and Masters, B. (1979) NADPH-cytochrome c (P450) reductase: spectrophotometric and stopped flow kinetic studies on the formation of reduced flavoprotein intermediates. J. Biol. Chem. 254, 7097-7104.
33. Burke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., and Mayer, R. T. (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34, 3337-3345.
34. Rendic, S., and DiCarlo, F. J. (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413-480.
35. Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., and Guengerich, F. P. (1997) Cooperativity in oxidation catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381.
36. 32P-adduct assay comparative recoveries of structurally diverse DNA adducts in the various enhancement procedures. Carcinogenesis 8, 1687-1693.
37. 32P-postlabeling analysis using different chromatographic procedures. Carcinogenesis 15, 1187-1192.
38. Stiborová, M., Frei, E., Sopko, B., Wiessler, M., and Schmeiser, H. H. (2002) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23, 617-625.
39. DeMarini, D. M., Abu-Shakra, A., Gupta, R., Hendee, L. J., and Levine, J. G. (1992) Molecular analysis of mutations induced by the intercalating agent ellipticine at the hisD3052 allele of Salmonella typhimurium TA98. Environ. Mol. Mutagen. 20, 12-18.
40. Aimová, D., and Stiborová, M. (2002) Interaction of anticancer drug ellipticine with cytochromes P450 dictates its physiological properties. Chem. Listy 96, 209.